Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.
Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.
Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.
Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.
Biological E. Limited, in partnership with Dynavax Technologies and Baylor College of Medicine, has initiated a Phase I/II clinical trial for its COVID-19 subunit vaccine candidate in India, receiving approval from the Drugs Controller General of India. The trial will involve approximately 360 healthy participants aged 18 to 65, evaluating the vaccine's safety and immunogenicity using an antigen from BCM Ventures and Dynavax's adjuvant CpG 1018. Results are anticipated by February 2021, marking a significant step in addressing the COVID-19 pandemic with a safe and affordable vaccine.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported third-quarter 2020 results, with HEPLISAV-B product revenue at $11.6 million, a rise from $10.2 million in 2019. The company highlighted a rebound in the adult hepatitis B vaccine market, achieving a 23% market share. Agreements with Valneva could yield $130 to $230 million in 2021 for its adjuvant, CpG 1018. Research and development expenses decreased to $8.5 million, while SG&A expenses rose to $21.5 million. Net income was $4.4 million, influenced by a $21.2 million gain in warrant liability.
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical firm focusing on vaccine development, announced that CEO Ryan Spencer will present at the Stifel 2020 Virtual Healthcare Conference on November 16 at 3:30 p.m. E.T. Investors can access the live audio webcast via the 'Events & Presentations' section on the company's website. A replay will be available for 30 days after the event. Dynavax's HEPLISAV-B® vaccine is approved for preventing hepatitis B in adults and is advancing its CpG 1018 vaccine adjuvant through various collaborations.
Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2020 financial results on November 5, 2020, after U.S. markets close. A conference call with live audio webcast is scheduled at 4:30 p.m. ET. The company is known for developing novel vaccines, including HEPLISAV-B®, a hepatitis B vaccine. Further developments include collaborations on adjuvanted vaccines targeting COVID-19 and influenza. For detailed information, visit www.dynavax.com.
Dynavax Technologies (DVAX) announced that Medigen Vaccine Biologics Corporation (MVC) received a Taiwan government subsidy of NT$ 472 million (US$ 16.4 million) for initiating a Phase 1 clinical trial of a COVID-19 vaccine. The trial, which started in early October, aims to evaluate the safety and immunogenicity of MVC's vaccine combined with Dynavax's CpG 1018 adjuvant. The study involves around 45 healthy participants, receiving two doses 28 days apart, demonstrating the potential for enhanced immune response against COVID-19.
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the appointment of Peter R. Paradiso, Ph.D., to its Board of Directors on September 24, 2020. With over 30 years of expertise in vaccine strategic planning, Paradiso is set to provide valuable guidance as the company expands its vaccine portfolio, particularly focusing on HEPLISAV-B and CpG 1018. Concurrently, Michael Ostrach, CFO and CBO, has announced his retirement planned for 2021. Dynavax will seek a successor while Ostrach continues until March 31, 2021, to ensure a smooth transition.
Valneva SE and Dynavax Technologies Corporation have formed a commercial partnership for the supply of Dynavax's CpG 1018 adjuvant to be used in Valneva's COVID-19 vaccine candidate, VLA2001. The UK government has agreed to purchase up to 190 million doses of VLA2001 over five years. Dynavax will supply the adjuvant necessary for 100 million doses in 2021, with an option for an additional 90 million doses by 2025. VLA2001 is expected to enter clinical studies by the end of 2020 and aims for regulatory approval in the second half of 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on September 14, 2020, at 10:00 a.m. ET. The event will be accessible via a webcast on the company's website under the 'Events & Presentations' section. Dynavax is focused on developing novel vaccines, including its first commercial product, HEPLISAV-B®, launched in February 2018, aimed at preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a $3.4 million grant from the Bill & Melinda Gates Foundation to scale up production of its CpG 1018 adjuvant, which supports COVID-19 vaccine development. This funding aims to increase manufacturing capacity to 750 million doses annually, potentially aiding global vaccine distribution. CEO Ryan Spencer emphasized the importance of adjuvants in enhancing vaccine effectiveness. CpG 1018 has a proven track record with the FDA-approved HEPLISAV-B hepatitis B vaccine.
Dynavax Technologies Corporation (DVAX) reported second quarter 2020 financial results, revealing net product revenue of $2.4 million, a decline from $8.3 million in Q2 2019, primarily due to a significant drop in adult hepatitis B vaccine utilization caused by the COVID-19 pandemic. Despite this setback, the company's prospects remain positive with ongoing collaborations to develop adjuvanted vaccines, including COVID-19. The net loss for the quarter was $51.6 million, or $0.53 per share, with a cash position of $200.7 million as of June 30, 2020.
